Novel IBD Drug Gets 20-Year China Patent Protection: $1B Market Opportunity for First-in-Class Treatment – Stock Titan

Novel IBD Drug Gets 20-Year China Patent Protection: $1B Market Opportunity for First-in-Class Treatment  Stock Titan